Cigna Group Targets $45 EPS by 2030 as Specialty Growth Offsets Pharmacy Headwinds
Cigna Group (CI) aims for $45 EPS by 2030, with specialty growth offsetting pharmacy challenges. The company expects $20B revenue growth from CuraScript by 2030. Cigna plans a 40% debt-to-capital ratio by 2026, enabling share buybacks and acquisitions. Medical cost trends align with expectations, with elevated but stable costs anticipated.
How this was made

The 30-second read
Why it matters
The new EPS and revenue targets may drive a re‑rating of the stock's valuation multiples.
Market read
Guidance update is a primary corporate disclosure for a large‑cap insurer, offering a fresh data point for valuation models.
What to watch
Potential regulatory changes to specialty pharmacy reimbursements could temper growth.
Background
Cigna's Accelerate to One program aims for $3B in savings and expands CuraScript specialty pharmacy revenue.
Ticker impact
Cigna disclosed new EPS target of $45 by 2030 and $25B CuraScript revenue goal, a fresh guidance update.
likely upward pressure as investors price in stronger long‑term earnings outlook
The $45 EPS target and $20B revenue add‑on are new, material numbers for a large‑cap insurer, prompting re‑valuation.
Market effects
May boost health‑insurance sector sentiment as Cigna signals strong specialty pharmacy growth.
U.S. market focus; limited direct regional effect.
Limited to investors tracking U.S. health‑care insurers.
Counterpoint
Guidance could be overly optimistic given rising drug costs and competitive pressures.
Key entities
- companyCigna Group
Global health services insurer (ticker CI).

